| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide an IL-21 variant having improved or alternative characteristics of IL-21, for example, activity, selectivity, stability, and circulation time or biological half-life. <P>SOLUTION: There is disclosed a human interleukin-21 (IL-21) variant where a human IL-21 variant peptide, in which an amino acid is deleted and/or substituted in the region comprising amino acid number 65 to 96, binds to a human IL-21 receptor. There is also disclosed a pharmaceutical composition for treating tumor containing the human IL-21 variant peptide as an active ingredient. <P>COPYRIGHT: (C)2012,JPO&INPIT |
